Areca Thirteen Pill Improves Depression in Rat by Modulation of the Chemokine/Chemokine Receptor Axis.

Chemokines Depression Neuroinflammation Proteomics

Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
19 Dec 2023
Historique:
received: 31 08 2023
accepted: 27 11 2023
medline: 19 12 2023
pubmed: 19 12 2023
entrez: 19 12 2023
Statut: aheadofprint

Résumé

Depressive disorder is a severe and complex mental illness. There are a few anti-depressive medications that can reduce depressive symptoms, but with adverse or side effects. GaoYou-13 (GY-13), commonly known as Areca Thirteen Pill, is a traditional medicine for depression treatment with significant clinical impact. However, the molecular mechanism of GY-13 has not been fully elucidated. This study aimed to explore and explain the action and mechanism of GY-13 in treatment for depression. SD male rats were stimulated differently daily for 42 days to construct a depression rat model and divided into six groups: the control, CUMS model, GY-13L, GY-13 M, GY-13H, and FLUO. The body weight of was measured on day 7, 14, 21, 28, 35, and 42 or different days, and the behavioral tests (Open-field test, Sucrose preference test, Morris water maze) were made alongside. After the rats were decapitated, the rat brains were stained with Nissl or H&E dyes. The serums of TNF-α and IL-1β were tested. The protein of p-IKKα, p-IкBα, and p-NFкBp65 was traced. Then nano-LC-MS/MS analysis was made to detect the mechanism of GY-13. The active ingredients, drug targets, and key pathways of GY-13 in treating depression were analyzed through network pharmacology and molecular docking. With immunohistochemistry, quantitative RT-PCR, and western-blot techniques, the therapeutic mechanism of GY-13 was traced and analyzed. This study revealed that GY-13 significantly enhances autonomous and exploratory behavior, sucrose consumption, learning and memory ability, and hippocampal neuronal degeneration, which inhibits inflammation. In addition, omics analysis showed several proteins were altered in the hippocampus of rats following CUMS and GY-13 treatment. Bioinformatics analysis and network pharmacology revealed the antidepressant effects of GY-13 are related to the chemokine/chemokine receptor axis. Immunohistochemistry, western blotting and RT-PCR assay further support the findings of omics analysis. We highlighted the importance of the chemokine/chemokine receptor axis in the treatment of depression, as well as showed GY-13 can be used as a novel targeted therapy for depression treatment.

Identifiants

DOI: 10.1007/s12035-023-03855-1 PMID: 38110645
pubmed: 38110645
doi: 10.1007/s12035-023-03855-1
pii: 10.1007/s12035-023-03855-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Natural Science Foundation of China
ID : 81760792
Organisme : Inner Mongolia Natural Science Foundation Projec
ID : 2021MS08078

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Rakel RE (1999) Depression. Prim Care 26(2):211–224. https://doi.org/10.1016/s0095-4543(08)70003-4
doi: 10.1016/s0095-4543(08)70003-4 pubmed: 10318745
Bouvier N, Trenque T, Millart H (2003) Development of antidepressant drugs. Experience and prospects. Presse Med 32(11):519–522
pubmed: 12733393
Zhang Y, Chen Y, Ma L (2018) Depression and cardiovascular disease in elderly: current understanding. J Clin Neurosci 47:1–5. https://doi.org/10.1016/j.jocn.2017.09.022
doi: 10.1016/j.jocn.2017.09.022 pubmed: 29066229
Dehn LB, Beblo T (2019) Depressed, biased, forgetful: the interaction of emotional and cognitive dysfunctions in depression. Neuropsychiatr 33(3):123–130. https://doi.org/10.1007/s40211-019-0307-4
doi: 10.1007/s40211-019-0307-4 pubmed: 30875025
Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R (2023) Novel and emerging treatments for major depression. Lancet 401(10371):141–153. https://doi.org/10.1016/s0140-6736(22)02080-3
doi: 10.1016/s0140-6736(22)02080-3 pubmed: 36535295
McCarron RM, Shapiro B, Rawles J, Luo J (2021) Depression. Ann Intern Med 174(5):Itc65-itc80. https://doi.org/10.7326/aitc202105180
doi: 10.7326/aitc202105180 pubmed: 33971098
Dong M, Wang SB, Li Y, Xu DD, Ungvari GS, Ng CH, Chow IHI, Xiang YT (2018) Prevalence of suicidal behaviors in patients with major depressive disorder in China: a comprehensive meta-analysis. J Affect Disord 225:32–39. https://doi.org/10.1016/j.jad.2017.07.043
doi: 10.1016/j.jad.2017.07.043 pubmed: 28779680
Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ (2009) What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60(11):1439–1445. https://doi.org/10.1176/ps.2009.60.11.1439
doi: 10.1176/ps.2009.60.11.1439 pubmed: 19880458
Jiang J, Yang M, Tian M, Chen Z, Xiao L, Gong Y (2023) Intertwined associations between oxytocin, immune system and major depressive disorder. Biomed Pharmacother 163:114852. https://doi.org/10.1016/j.biopha.2023.114852
doi: 10.1016/j.biopha.2023.114852 pubmed: 37163778 pmcid: 10165244
Galley JD, Mashburn-Warren L, Blalock LC, Lauber CL, Carroll JE, Ross KM, Hobel C, Coussons-Read M, Dunkel Schetter C, Gur TL (2023) Maternal anxiety, depression and stress affects offspring gut microbiome diversity and bifidobacterial abundances. Brain Behav Immun 107:253–264. https://doi.org/10.1016/j.bbi.2022.10.005
doi: 10.1016/j.bbi.2022.10.005 pubmed: 36240906
Hurley LL, Tizabi Y (2013) Neuroinflammation, neurodegeneration, and depression. Neurotox Res 23(2):131–144. https://doi.org/10.1007/s12640-012-9348-1
doi: 10.1007/s12640-012-9348-1 pubmed: 22895696
Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C (2023) Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. Transl Psychiatry 13(1):5. https://doi.org/10.1038/s41398-022-02297-y
doi: 10.1038/s41398-022-02297-y pubmed: 36624089 pmcid: 9829236
Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, Brizard B, El Hage W, Surget A, Belzung C, Camus V (2021) Neuroinflammation and depression: a review. Eur J Neurosci 53(1):151–171. https://doi.org/10.1111/ejn.14720
doi: 10.1111/ejn.14720 pubmed: 32150310
Evrensel A, Ünsalver B, Ceylan ME (2020) Neuroinflammation gut-brain axis and depression. Psychiatry Investig 17(1):2–8. https://doi.org/10.30773/pi.2019.08.09
doi: 10.30773/pi.2019.08.09 pubmed: 31587531
Maes M, Abe Y, Sirichokchatchawan W, Suwimonteerabutr J, Sangkomkamhangd U, Almulla AF, Satthapisit S (2023) The cytokine, chemokine, and growth factor network of prenatal depression. Brain Sci 13(5).  https://doi.org/10.3390/brainsci13050727
Takacs GP, Flores-Toro JA, Harrison JK (2021) Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy. Pharmacol Ther 222:107790. https://doi.org/10.1016/j.pharmthera.2020.107790
doi: 10.1016/j.pharmthera.2020.107790 pubmed: 33316289
Trojan E, Ślusarczyk J, Chamera K, Kotarska K, Głombik K, Kubera M, Basta-Kaim A (2017) The modulatory properties of chronic antidepressant drugs treatment on the brain chemokine - chemokine receptor network: a molecular study in an animal model of depression. Front Pharmacol 8:779. https://doi.org/10.3389/fphar.2017.00779
doi: 10.3389/fphar.2017.00779 pubmed: 29163165 pmcid: 5671972
Cai MY, Yang Z, Huang XJ, Li J, Bao WY, Hurilebagen W, Wuyunsiriguleng CJW, Ma LQ, Tong HY (2022) Mongolian Medicine Areca Thirteen Pill (GY-13) Improved depressive syndrome via upregulating cAMP/PKA/CREB/BDNF signaling pathway. J Ethnopharmacol 293:115310. https://doi.org/10.1016/j.jep.2022.115310
doi: 10.1016/j.jep.2022.115310 pubmed: 35452773
Kitano H (2002) Systems biology: a brief overview. Science 295(5560):1662–1664. https://doi.org/10.1126/science.1069492
doi: 10.1126/science.1069492 pubmed: 11872829
Zheng P, Chen JJ, Zhou CJ, Zeng L, Li KW, Sun L, Liu ML, Zhu D, Liang ZH, Xie P (2016) Identification of sex-specific urinary biomarkers for major depressive disorder by combined application of NMR- and GC-MS-based metabonomics. Transl Psychiatry 6(11):e955. https://doi.org/10.1038/tp.2016.188
doi: 10.1038/tp.2016.188 pubmed: 27845778 pmcid: 5314113
Zhang Y, Yuan S, Pu J, Yang L, Zhou X, Liu L, Jiang X, Zhang H, Teng T, Tian L, Xie P (2018) Integrated metabolomics and proteomics analysis of hippocampus in a rat model of depression. Neuroscience 371:207–220. https://doi.org/10.1016/j.neuroscience.2017.12.001
doi: 10.1016/j.neuroscience.2017.12.001 pubmed: 29237567
Sissolak B, Zabik C, Saric N, Sommeregger W, Vorauer-Uhl K, Striedner G (2019) Application of the Bradford assay for cell lysis quantification: residual protein content in cell culture supernatants. Biotechnol J 14(7):e1800714. https://doi.org/10.1002/biot.201800714
doi: 10.1002/biot.201800714 pubmed: 30983130
Slomski A (2020) Online mindfulness therapy improves residual depression. JAMA 323(12):1124. https://doi.org/10.1001/jama.2020.2446
doi: 10.1001/jama.2020.2446 pubmed: 32207796
Tang SW, Tang WH, Leonard BE (2017) Multitarget botanical pharmacotherapy in major depression: a toxic brain hypothesis. Int Clin Psychopharmacol 32(6):299–308. https://doi.org/10.1097/yic.0000000000000186
doi: 10.1097/yic.0000000000000186 pubmed: 28657934
Pan L, Li Z, Wang Y, Zhang B, Liu G, Liu J (2020) Network pharmacology and metabolomics study on the intervention of traditional Chinese medicine Huanglian Decoction in rats with type 2 diabetes mellitus. J Ethnopharmacol 258:112842. https://doi.org/10.1016/j.jep.2020.112842
doi: 10.1016/j.jep.2020.112842 pubmed: 32333952
Chen X, Hu Q, Zhang K, Teng H, Li M, Li D, Wang J, Du Q, Zhao M (2020) The clock-controlled chemokine contributes to neuroinflammation-induced depression. Faseb j 34(6):8357–8366. https://doi.org/10.1096/fj.201900581RRR
doi: 10.1096/fj.201900581RRR pubmed: 32329129
Zhou S, Chen R, She Y, Liu X, Zhao H, Li C, Jia Y (2022) A new perspective on depression and neuroinflammation: non-coding RNA. J Psychiatr Res 148:293–306. https://doi.org/10.1016/j.jpsychires.2022.02.007
doi: 10.1016/j.jpsychires.2022.02.007 pubmed: 35193033
Veenstra M, Ransohoff RM (2012) Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller? J Neuroimmunol 246(1–2):1–9. https://doi.org/10.1016/j.jneuroim.2012.02.016
doi: 10.1016/j.jneuroim.2012.02.016 pubmed: 22445294 pmcid: 3335977
Pawlik K, Piotrowska A, Kwiatkowski K, Ciapała K, Popiolek-Barczyk K, Makuch W, Mika J (2020) The blockade of CC chemokine receptor type 1 influences the level of nociceptive factors and enhances opioid analgesic potency in a rat model of neuropathic pain. Immunology 159(4):413–428. https://doi.org/10.1111/imm.13172
doi: 10.1111/imm.13172 pubmed: 31919846 pmcid: 7078003
Miller MC, Mayo KH (2017) Chemokines from a Structural Perspective. Int J Mol Sci 18(10):2088. https://doi.org/10.3390/ijms18102088
Griffith JW, Sokol CL, Luster AD (2014) Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 32:659–702. https://doi.org/10.1146/annurev-immunol-032713-120145
doi: 10.1146/annurev-immunol-032713-120145 pubmed: 24655300
Rot A, von Andrian UH (2004) Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22:891–928. https://doi.org/10.1146/annurev.immunol.22.012703.104543
doi: 10.1146/annurev.immunol.22.012703.104543 pubmed: 15032599
Yuan Q, Bromley SK, Means TK, Jones KJ, Hayashi F, Bhan AK, Luster AD (2007) CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med 204(6):1327–1334. https://doi.org/10.1084/jem.20062076
doi: 10.1084/jem.20062076 pubmed: 17548518 pmcid: 2118617
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949. https://doi.org/10.1038/nm1093
doi: 10.1038/nm1093 pubmed: 15322536
Li W, Liu X, Qiao H (2020) Downregulation of hippocampal SIRT6 activates AKT/CRMP2 signaling and ameliorates chronic stress-induced depression-like behavior in mice. Acta Pharmacol Sin 41(12):1557–1567. https://doi.org/10.1038/s41401-020-0387-5
doi: 10.1038/s41401-020-0387-5 pubmed: 32265492 pmcid: 7921578
Qiu Y, Hao ML, Cheng XT, Hua Z (2020) Bioinformatics analysis of genes and mechanisms in postherpetic neuralgia. Pain Res Manag 2020:1380504. https://doi.org/10.1155/2020/1380504
doi: 10.1155/2020/1380504 pubmed: 33029266 pmcid: 7532419
Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, Zhang JQ, Walczak EG, Kazmi MA, Taylor BS, Huber T, Chi P, Sakmar TP, Chen Y (2016) Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 48(6):675–680. https://doi.org/10.1038/ng.3549
doi: 10.1038/ng.3549 pubmed: 27089179 pmcid: 5032652
Meijsen JJ, Shen H, Vemuri M, Rasgon NL, Koenen KC, Duncan LE (2021) Shared genetic influences on depression and menopause symptoms. Psychol Med 53(6):2241–2251. https://doi.org/10.1017/s0033291721004037
Stamatovich SN, Lopez-Gamundi P, Suchting R, Colpo GD, Walss-Bass C, Lane SD, Schmitz JM, Wardle MC (2021) Plasma pro- and anti-inflammatory cytokines may relate to cocaine use, cognitive functioning, and depressive symptoms in cocaine use disorder. Am J Drug Alcohol Abuse 47(1):52–64. https://doi.org/10.1080/00952990.2020.1828439
doi: 10.1080/00952990.2020.1828439 pubmed: 33119414
Stilling RM, van de Wouw M, Clarke G, Stanton C, Dinan TG, Cryan JF (2016) The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis? Neurochem Int 99:110–132. https://doi.org/10.1016/j.neuint.2016.06.011
doi: 10.1016/j.neuint.2016.06.011 pubmed: 27346602
Wong WLE, Dawe GS, Young AH (2021) The putative role of the relaxin-3/RXFP3 system in clinical depression and anxiety: a systematic literature review. Neurosci Biobehav Rev 131:429–450. https://doi.org/10.1016/j.neubiorev.2021.09.028
doi: 10.1016/j.neubiorev.2021.09.028 pubmed: 34537263
Lin E, Kuo PH, Liu YL, Yu YW, Yang AC, Tsai SJ (2018) A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers. Front Psychiatry 9:290. https://doi.org/10.3389/fpsyt.2018.00290
doi: 10.3389/fpsyt.2018.00290 pubmed: 30034349 pmcid: 6043864

Auteurs

Jing-Jing Bai (JJ)

Tongliao Institute of agriculture and animal husbandry, Tongliao, Inner Mongolia, People's Republic of China.

Min Ao (M)

Affiliated Hospital of Inner Mongolia Minzu University, No. 1472 Holin He Street, Tongliao, Inner Mongolia, People's Republic of China.

An Xing (A)

Affiliated Hospital of Inner Mongolia Minzu University, No. 1472 Holin He Street, Tongliao, Inner Mongolia, People's Republic of China.

Li-Jun Yu (LJ)

Inner Mongolia Minzu University, Tongliao, Inner Mongolia, People's Republic of China.

Hai-Ying Tong (HY)

Affiliated Hospital of Inner Mongolia Minzu University, No. 1472 Holin He Street, Tongliao, Inner Mongolia, People's Republic of China.

Wu-Ye Bao (WY)

Affiliated Hospital of Inner Mongolia Minzu University, No. 1472 Holin He Street, Tongliao, Inner Mongolia, People's Republic of China. 436042593@qq.com.

Yu Wang (Y)

Key Laboratory of Basic Pharmacology of Ministry of Education, Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, 563006, People's Republic of China. shen348@126.com.
ORCID: 0000-0003-1557-4771

Classifications MeSH